Gilead Expands its Collaboration with AbCellera to Develop Antibodies Against Multiple Indications

 Gilead Expands its Collaboration with AbCellera to Develop Antibodies Against Multiple Indications

Gilead Expands its Collaboration with AbCellera to Develop Antibodies Against Multiple Indications

Shots:

  • AbCellera to receive upfront, milestone, and royalties based on the development and commercialization of Abs, emerge under the collaboration
  • The expanded collaboration will utilize AbCellera’s technology stack, which includes Trianni Mouse and OrthoMab protein engineering platform
  • AbCellera will generate panels of Abs against up to 8 new targets across multiple indications, selected by Gilead

Click here to­ read full press release/ article | Ref: BusinessWire | Image: Business In Vancouver

Tuba Khan

Tuba Khan is Senior Editor at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in the Life sciences industry. She covers Biopharma, MedTech, and Digital health segments. Tuba also has an experience of digital and social media marketing and runs the campaigns independently. She can be contacted on tuba@pharmashots.com

Related post